CClinicalTrials.gg
Active, not recruitingNCT06073717BRAINonFITUpdated May 4, 2026

Motor-cognitive Training Effects on Cognition in Breast Cancer Survivors: the BRAINonFIT Study (BRAINonFIT).

An interventional study of Exercise and Motor-cognitive Training in Breast Cancer Survivors, Cognitive Impairment and Executive Dysfunction, sponsored by University of Seville. Active, not recruiting at 3 sites in Spain. Open to female participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by University of Seville · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
Female
01

Study summary

The goal of this interventional study is to assess the effects of either physical exercise program or combined with cognitive training (dual motor and cognitive training program) on breast cancer survivors. The main questions it aims to answer are:

  • Analyze the effectiveness of a supervised dual-task training program or a physical exercise program on the executive functions of the participants.
  • Evaluate the impact of both interventions on physical function, emotional aspects, and important biomarkers related to muscle-brain crosstalk.

Participants will perform a 20-week supervised and controlled program, three times a week, along with weekly calorie and step challenges.

Researchers will compare the dual-task training group, with the physical exercise group, and with a control group, which will perform the guideline recommendations of physical activity (non-supervised) to see how these intervention approaches can impact cognitive functions, physical functions, emotional aspects, and biomarkers related to muscle-brain crosstalk.

Assessments will take place at three-time points: at baseline, after the intervention (20 weeks post-baseline) and after a 12-week follow-up period (32 weeks post-baseline).

02

Conditions studied

  • Breast Cancer Survivors
  • Cognitive Impairment
  • Executive Dysfunction

Keywords

  • Cancer-related Cognitive Impairment
  • Physical exercise
  • dual motor-cognitive tasks
  • cognitive stimulation
  • Neurocognitive disorders
03

In context

Cognitive Dysfunction

3,843 studies on the registry are indexed under Cognitive Dysfunction; 1,100 are open to participants now.

This study's planned enrollment of 108 is above the median of 65 across 2,808 interventional studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

University of Seville is the lead sponsor of 127 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosed with stage I-IIIA breast cancer
  • Completed primary treatment, including surgery, radiotherapy and/or chemotherapy
  • Scheduled to receive adjuvant endocrine therapy, or currently receiving adjuvant endocrine therapy
  • Without functional limitations or other illnesses that condition and prevent them from practising intense physical exercise
  • FACT-Cog questionnaire score ≥ 10th percentile considering age groups
  • Fluency in Spanish (spoken and written)

Exclusion criteria

Exclusion Criteria:

  • Undergoing radiotherapy and/or chemotherapy
  • FACT-Cog questionnaire score ≤ 10th percentile considering age groups
  • Congenital heart disease
  • Chronic lung disease
  • Severe psychiatric disorders
  • History of substance abuse, or dependence (other than tobacco)
  • Mood disorders require treatment (anxiety or depression)
  • Relapses (2-3 months before the study start)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Exercise Intervention

    This arm will receive a 5-month (20 weeks) supervised exercise program based on aerobic and resistance/strength training together with a weekly calorie or step challenge.

    Behavioral: Exercise

  • Experimental
    Dual Motor-Cognitive Intervention

    This arm will receive a 5-month (20 weeks) supervised and simultaneous dual-task program based on aerobic, resistance, and cognitive stimulation training together with a weekly calorie or step challenge

    Behavioral: Motor-cognitive Training

  • Active comparator
    Health and Wellness Intervention

    This arm will receive a 5-month health and wellness program.

    Behavioral: Health and Wellness

Interventions

  • BehavioralExercise

    Participants will complete a 5-month exercise program structured in 4 blocks of 5 weeks. Three supervised and combined aerobic/strength exercise sessions each week will be performed together with an aerobic weekly challenge. Aerobic exercise will be performed for 20-30 minutes using a treadmill, bicycle, or circuit training at light to moderate intensities (40-75% of heart rate reserve) during the first two blocks; gradually achieving high intensity (\>75% of HHR) in the last two blocks. Heart rate and the subjective perception of the exertion scale (6-20 Borg scale) will be monitored. Strength exercises will be started at light to moderate intensities (2 sets of 15-20 repetitions at 40-50% of repetition maximum), performed muscle actions at high intensities in the last two blocks (2 sets of 8-15 repetitions at 50-75% RM); using elastic bands, free weights, and weights gym exercises.

  • BehavioralMotor-cognitive Training

    Participants will complete the same four-block exercise program in terms of type, frequency, intensity, and volume of physical/motor training. Simultaneous with the progression of physical/motor training, the complexity of cognitive stimulation will be increased according to the performance of the participants. General dual-task training will be performed, which describes the use of a physical/motor intervention with different cognitive stimulations (memory, language, intelligence, attention, processing speed, calculation, inhibitory control) that are not specific to the methods to be used for their assessment.

  • BehavioralHealth and Wellness

    Participants randomly assigned to the health and wellness group will be advised and re-educated to support and improve health aspects. Participants in this group will aim to achieve the physical activity recommendations, and in addition, they will receive bi-weekly emails and phone call coaching with tools to empower patients with knowledge about physical exercise, nutrition, and brain health guidelines. Following completion of the 5-month exercise program, this group will receive an exercise program for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Executive Function (Cognitive Flexibility and Processing Speed)

    Trail Making Test A and B (minimum and maximum values, defined by the time in seconds, depend on the age- and education-normalised groups; higher scores mean worse results)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

Secondary outcomes

  1. Inhibitory Control and Concentration

    Stroop Color and Word test (minimum and maximum values, defined by the time in seconds, depend on the age- and education-normalised groups; higher scores mean worse results)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  2. Verbal Intelligence, Non-verbal Intelligence, Verbal memory, and Non-verbal Memory

    Reynolds Intellectual Assessment Scale (Global index values range from ≤ 69 to ≥ 130, mean value of 100; higher scores mean better results)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  3. Learning Ability

    Wechsler Memory Scale subtest "word pairs" (The subtest score range from 40 to 60, mean value of 100; higher scores mean better results)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  4. Perceived Cognitive Functions

    Functional Assessment of Cancer Therapy: Cognition (FACT-Cog) (Total score ranges from 0 to 148; higher scores mean better results)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  5. Max. Oxygen Consumption

    Modified Bruce Test (80% sub-max)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  6. Muscular Strength of shoulder and knee extensors

    Isokinetic dynamometer

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  7. Range of Movement

    Manual Goniometer

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  8. Forced Vital Capacity (FVC) and Forced Expiratory Volume (FEV)

    Spirometry (FEV/FVC ratio, represented in percentages)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  9. Volume of physical activity

    Accelerometer (Volume in minutes per week)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  10. Intensity of Physical Activity

    Accelerometer (Intensity in metabolic equivalents)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  11. Weight and Height

    Body Mass Index (weight and height will be combined to report BMI in kg/m\^2)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  12. Brain-Derived Neurotrophic Factor (BDNF), Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor 17 (FDF-17), Soluble Klotho (S-KL)

    Concentration of these proteins in plasma by ELISA kit (Concentration of these proteins will be expressed in pg/mL or ng/mL)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  13. Fatigue

    Functional Assessment of Chronic Illness Therapy: Fatigue (FACIT-F) (Total score range from 0 to 52; higher scores mean better results)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  14. Pain Scale

    Visual Analogue Scale (Total score ranges from 0 to 10; higher scores mean worse results)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  15. Depression

    Back Depression Inventory (Total score ranges from 0 to 63; higher scores mean worse results)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

  16. Anxiety

    State-Trait Anxiety Inventory (The score ranges from 20 to 80; higher scores mean worse results)

    Time frame: Baseline (week 0); Post-intervention (25 weeks post-baseline); and Post-follow up (32 weeks post-baseline)

07

Study locations

3 sites
  • SADUS - Servicio de Actividades Deportivas de la Universidad de Sevilla
    Seville, Sevilla 41012, Spain
  • Laboratorio de Ciencias del Deporte
    Seville, Sevilla 41013, Spain
  • Oncoavanze
    Seville, Sevilla 41013, Spain
08

References and documents

Publications

  • Jesus OJ, Luis CP, Matilde MF. Effects of exercise on cancer-related cognitive impairment in breast cancer survivors: a scoping review. Breast Cancer. 2023 Nov;30(6):885-909. doi: 10.1007/s12282-023-01484-z. Epub 2023 Jul 22. PubMed 37480454 ↗
  • Orellana-Jaen J, Mora-Fernandez M, Carrasco-Paez L. Effects of a motor and cognitive training program on executive function and different biomarkers related to muscle-brain crosstalk in breast cancer survivors: 3-arm randomised controlled BRAINonFIT study protocol. Contemp Clin Trials. 2024 Nov;146:107672. doi: 10.1016/j.cct.2024.107672. Epub 2024 Sep 10. PubMed 39265784 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06073717
Lead sponsor
University of Seville
Responsible party
Jesus Orellana Jaen (Principal Investigator, University of Seville) — Principal investigator
First posted
Oct 10, 2023
Start date
Oct 1, 2024
Primary completion
Sep 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 4, 2026

Study contacts

Matilde Mora Fernández, PhD
study director · University of Seville
Luis Carrasco Páez, PhD
study director · University of Seville
Jesús Orellana Jaén
principal investigator · University of Seville

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion